Trial · NCT05097989
Participant flow108
How many started, completed or left each group, period by period.
1 to 20 of 108
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Initial Evaluation Period (26 Weeks) | STARTED | IgAN Cohort: ALXN2050 120 mg | 9 | |
| Initial Evaluation Period (26 Weeks) | STARTED | IgAN Cohort: ALXN2050 180 mg | 26 | |
| Initial Evaluation Period (26 Weeks) | STARTED | IgAN Cohort: Placebo | 26 | |
| Initial Evaluation Period (26 Weeks) | STARTED | IgAN Cohort: Placebo to ALXN2050 120 mg | 0 | |
| Initial Evaluation Period (26 Weeks) | STARTED | IgAN Cohort: Placebo to ALXN2050 180 mg | 0 | |
| Initial Evaluation Period (26 Weeks) | STARTED | LN Cohort: ALXN2050 120 mg | 6 | |
| Initial Evaluation Period (26 Weeks) | STARTED | LN Cohort: ALXN2050 180 mg | 17 | |
| Initial Evaluation Period (26 Weeks) | STARTED | LN Cohort: Placebo | 16 | |
| Initial Evaluation Period (26 Weeks) | STARTED | LN Cohort: Placebo to Standard-of-care Background Therapy | 0 | |
| Initial Evaluation Period (26 Weeks) | Received at Least 1 Dose of Study Drug | IgAN Cohort: ALXN2050 120 mg | 9 | |
| Initial Evaluation Period (26 Weeks) | Received at Least 1 Dose of Study Drug | IgAN Cohort: ALXN2050 180 mg | 26 | |
| Initial Evaluation Period (26 Weeks) | Received at Least 1 Dose of Study Drug | IgAN Cohort: Placebo | 26 | |
| Initial Evaluation Period (26 Weeks) | Received at Least 1 Dose of Study Drug | IgAN Cohort: Placebo to ALXN2050 120 mg | 0 | |
| Initial Evaluation Period (26 Weeks) | Received at Least 1 Dose of Study Drug | IgAN Cohort: Placebo to ALXN2050 180 mg | 0 | |
| Initial Evaluation Period (26 Weeks) | Received at Least 1 Dose of Study Drug | LN Cohort: ALXN2050 120 mg | 6 | |
| Initial Evaluation Period (26 Weeks) | Received at Least 1 Dose of Study Drug | LN Cohort: ALXN2050 180 mg | 17 | |
| Initial Evaluation Period (26 Weeks) | Received at Least 1 Dose of Study Drug | LN Cohort: Placebo | 16 | |
| Initial Evaluation Period (26 Weeks) | Received at Least 1 Dose of Study Drug | LN Cohort: Placebo to Standard-of-care Background Therapy | 0 | |
| Initial Evaluation Period (26 Weeks) | COMPLETED | IgAN Cohort: ALXN2050 120 mg | 9 | |
| Initial Evaluation Period (26 Weeks) | COMPLETED | IgAN Cohort: ALXN2050 180 mg | 26 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05097989/flow